Table 4.

Univariate and multivariable analyses of risk factors for biochemical failure, and clinical failure

Factor	Univariate			Multivariable
	HR	95% CI	p	HR	95% CI	p
Biochemical failure
GS sum; ≥ 8 vs. ≤ 7	1.478	0.9817–2.226	0.061	1.447	0.8568–2.442	0.17
iPSA;
20–30 vs. ≤ 20 ng/mL	1.141	0.7065–1.842	0.59	2.165	1.195–3.923	0.011
> 30 vs. ≤ 20 ng/mL	2.655	1.786–3.946	< 0.001	3.172	1.858–5.418	< 0.001
T stage;
T3a vs. T1–2	0.7803	0.524–1.162	0.22	1.017	0.561–1.845	0.95
T3b–4 vs. T1–2	2.223	1.465–3.373	< 0.001	1.902	1.02–3.548	0.043
Cores with GS sum 8–10; ≥ 5 vs ≤ 4	2.515	1.664–3.8	< 0.001	1.262	0.6974–2.283	0.44
Prescription dose; 74 Gy vs 78 Gy	0.7679	0.4577–1.288	0.32	0.975	0.5704–1.666	0.93
Clinical failure
GS sum; ≥ 8 vs. ≤ 7	2.103	1.116–3.964	0.022	1.769	0.8323–3.761	0.14
iPSA;
20–30 vs. ≤ 20 ng/mL	0.7025	0.3158–1.563	0.39	0.7985	0.309–2.063	0.64
> 30 vs. ≤ 20 ng/mL	1.606	0.8922–2.89	0.11	1.126	0.5344–2.373	0.75
T stage;
T3a vs. T1–2	0.7314	0.4052–1.32	0.3	1.029	0.4429–2.39	0.95
T3b–4 vs. T1–2	2.199	1.209–3.999	0.0098	1.908	0.8119–4.484	0.14
Cores with GS sum 8–10; ≥ 5 vs ≤ 4	2.846	1.557–5.204	< 0.001	1.821	0.8307–3.992	0.13
Prescription dose; 74 Gy vs 78 Gy	0.4802	0.1913–1.205	0.12	0.5038	0.1937–1.31	0.16

HR hazard ratio, 95% CI 95% confidence interval, GS Gleason score, iPSA pretreatment prostate-specific antigen